(FORT WORTH, TX) —HEALTHPOINT, Ltd. today announced that it has enrolled the first of a planned 235 subjects into a Phase II dose response study investigating an experimental, cell-based wound therapy ---HP802-247---intended for the treatment of venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The first patient was enrolled at The Center for Clinical Research near San Francisco, Calif., led by the site’s principal investigator, Alexander Reyzelman, DPM. The study is being conducted by 28 investigators in 18 states.